Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBITDA (2019 - 2025)

IDEAYA Biosciences' EBITDA history spans 7 years, with the latest figure at -$83.1 million for Q4 2025.

  • For Q4 2025, EBITDA rose 37.71% year-over-year to -$83.1 million; the TTM value through Dec 2025 reached -$112.2 million, up 59.07%, while the annual FY2025 figure was -$112.2 million, 59.07% up from the prior year.
  • EBITDA for Q4 2025 was -$83.1 million at IDEAYA Biosciences, down from $119.8 million in the prior quarter.
  • Across five years, EBITDA topped out at $119.8 million in Q3 2025 and bottomed at -$133.3 million in Q4 2024.
  • The 5-year median for EBITDA is -$25.0 million (2022), against an average of -$30.4 million.
  • The largest annual shift saw EBITDA plummeted 2274.8% in 2023 before it surged 357.2% in 2025.
  • A 5-year view of EBITDA shows it stood at -$18.9 million in 2021, then decreased by 22.23% to -$23.1 million in 2022, then plummeted by 41.5% to -$32.6 million in 2023, then tumbled by 308.47% to -$133.3 million in 2024, then soared by 37.71% to -$83.1 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's EBITDA are -$83.1 million (Q4 2025), $119.8 million (Q3 2025), and -$77.6 million (Q2 2025).